

B' At Page 4, line 12, after "sequences," insert --(SEQ ID NO:22) through (SEQ ID NO:25)--.

B<sup>a</sup> At Page 4, line 15, after "sequences," insert --(SEQ ID NO:26) through (SEQ ID NO:29)--.

At Page 4, line 23, after "grafting," insert --(SEQ ID NO:30)--.

At Page 4, line 23, after "grafted V<sub>H</sub>," insert --(SEQ ID NO:31)--.

At Page 4, line 24, after "Mab 1129V<sub>H</sub>," insert --(SEQ ID NO:32)--.

At Page 4, line 30, after "grafting," insert --(SEQ ID NO:33)--.

At Page 4, line 30, after "grafted V<sub>L</sub>," insert --(SEQ ID NO:34)--.

At Page 4, line 31, after "Mab 1129V<sub>L</sub>," insert --(SEQ ID NO:35)--.

At Page 10, line 7, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:1)--.

At Page 10, line 9, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:2)--.

At Page 10, line 27, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:3)--.

At Page 10, line 28, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:4)--.

At Page 16, line 24, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:1)--.

At Page 16, line 26, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:5)--.

0915120-09198

At Page 16, line 28, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:6)--.

At Page 16, line 30, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:7)--.

At Page 16, line 32, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:8)--.

At Page 17, line 2, after the oligonucleotide sequence set forth, insert --(SEQ ID NO:9)--.

At Page 18, line 18, after "(Figure 9)," insert --(SEQ ID NO:36) through (SEQ ID NO:42)--.

Kindly insert the accompanying sequence listing between the specification and claims.

N.E.  
Kindly replace Figure 7 with the corrected Figure 7 accompanying this preliminary amendment.

IN THE CLAIMS:

Cancel Claims 5, 8, 9, 11, 12, and 14-20 without prejudice.

Amend the following claims:

1. (Amended) A human-murine [chimeric] antibody against respiratory syncytial virus, comprising:

a human antibody containing at least one CDR from each of the variable heavy and variable light chains of a [non-human] murine monoclonal antibody against [RSV] respiratory syncytial virus.